Fate Therapeutics Inc (FATE)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$1.23
Buy
$1.24
$0.04 (+3.33%)
Prices updated at 01 Apr 2026, 21:10 EDT
| Prices minimum 15 mins delay
Prices in USD
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 14m | 7m | |
| - | - | |
| -196m | -148m | |
| -1,434.52 | -2,222.45 | |
| -186m | -136m | |
| -177m | -135m | |
| Sales, General and administrative | 74m | 47m |
| Interest expenses | - | - |
| Provision for income taxes | - | - |
| Operating expenses | 209m | 154m |
| Income before taxes | -186m | -136m |
| Net income available to common shareholders | -186m | -136m |
| -1.64 | -1.15 | |
| Net interest income | 17m | 11m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -1.64 | -1.15 |
| Free cash flow per share | -1.2171 | -0.9746 |
| Book value/share | 3.1803 | 2.029 |
| Debt equity ratio | 0.244253 | 0.353734 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 292m | 209m |
| Current liabilities | 39m | 36m |
| Total capital | 319m | 207m |
| Total debt | 85m | 78m |
| Total equity | 319m | 207m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 441m | 319m |
| Total liabilities | - | - |
| Cash and cash equivalents | 36m | 47m |
| Common stock | 114m | 115m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 57m | 46m |
| Cash dividends paid | - | - |
| -124m | -112m | |
| Investments (gains) losses | 12m | 111m |
| 46m | 57m | |
| Net income | - | - |
| -123m | -106m | |
| -730,000 | -6m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
